BACKGROUND: Telomerase activity in leukemic blasts frequently is increased among patients with high-risk acute myeloid leukemia (AML). In the current study, the authors evaluated the feasibility, safety, immunogenicity, and therapeutic potential of human telomerase reverse transcriptase (hTERT)-expressing autologous dendritic cells (hTERT-DCs) in adult patients with AML. METHODS: hTERTDCs were produced from patient-specific leukapheresis, electroporated with an mRNA-encoding hTERT and a lysosomal-targeting sequence, and cryopreserved. A total of 22 patients with a median age of 58 years (range, 30-75 years) with intermediate-risk or high-risk AML in first or second complete remission (CR) were enrolled. hTERT-DCs were generated for 24 patients (73%). A median of 17 intradermal vaccinations (range, 6-32 intradermal vaccinations) containing 1310 7 cells were administered as 6 weekly injections followed by 6 biweekly injections. A total of 21 patients (16 in first CR, 3 in second CR, and 2 with early disease recurrence) received hTERT-DCs. RESULTS: hTERT-DCs were well tolerated with no severe toxicities reported, with the exception of 1 patient who developed idiopathic thrombocytopenic purpura. Of the 19 patients receiving hTERT-DCs in CR, 11 patients (58%) developed hTERTspecific T-cell responses that primarily were targeted toward hTERT peptides with predicted low human leukocyte antigen (HLA)-binding affinities. With a median follow-up of 52 months, 58% of patients in CR (11 of 19 patients) were free of disease recurrence at the time of their last follow-up visit; 57% of the patients who were aged 60 years (4 of 7 patients) also were found to be free of disease recurrence at a median follow-up of 54 months. CONCLUSIONS: The generation of hTERT-DCs is feasible and vaccination with hTERT-DCs appears to be safe and may be associated with favorable recurrence-free survival. Cancer 2017;123:3061-72. V C 2017 American Cancer Society.
INTRODUCTION
The treatment of patients with acute myeloid leukemia (AML) using the combination of cytarabine and anthracycline is associated with initial responses but a high frequency of disease recurrence. [1] [2] [3] Historically, allogeneic hematopoietic stem cell transplantation was not considered to be a viable option for a majority of patients with AML due to advanced age, comorbidities, lack of suitable donors, and transplantation-related complications. 4, 5 Although other therapeutic interventions have been explored for the treatment of AML, 6 their lack of activity or associated toxicities have had limited impact on the treatment paradigms for patients with AML. [6] [7] [8] [9] To circumvent these limiting factors, various autologous immunotherapeutic strategies using peptide vaccines or whole-cell approaches, with and without dendritic cells (DCs) as antigenpresenting cells, were developed with the goal of eliciting tumor-specific responses. [10] [11] [12] Telomerase, the ribonucleoprotein that synthesizes telomeric DNA, is substantially upregulated in cancer cells and plays an essential role in extending the proliferative lifespan of tumor cells. [13] [14] [15] [16] [17] Telomerase is highly upregulated in patients with AML, especially those with the high-risk cytogenetic subtypes, and therefore is considered an important leukemia-associated antigen candidate. [13] [14] [15] [16] [17] [18] [19] Telomerasebased cancer immunotherapies previously have been successfully generated and safely administered in patients with solid tumors. 20, 21 Mature DCs are potent antigen-presenting cells that modulate immune responses and can be generated easily from peripheral blood mononuclear cells (PBMCs) and loaded with specific antigens. [22] [23] [24] [25] The injection of mature DCs pulsed with peptides, proteins, or genes encoding antigens have elicited antigen-specific antitumor responses in preclinical experiments, animal models, and clinical studies. [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] Indeed, DCs modified by putative tumor antigens such as lymphoma idiotype protein, 30 prostate alkaline phosphatase, 32 colorectal antigen peptides, 35 and tumor lysates 36 have been administered to patients and detectable antitumor immune responses were observed. In addition, DCs can be pulsed with translatable mRNA, which allows the host's human leukocyte antigen (HLA) molecules to preferentially select and present epitopes from the antigen's amino acid repertoire. 28 AST-VAC1 (formerly known as GRNVAC1, also referred to herein as hTERT-DC) is an immunotherapeutic product that comprises mature DCs transfected with mRNA-encoding telomerase (human telomerase reverse transcriptase [hTERT] ) and the lysosomal targeting signal lysosomal-associated membrane protein (LAMP), 38 which enhances immunostimulatory activity. 39 In vitro studies have demonstrated that autologous hTERT-DCs stimulate hTERT-specific T cells from the PBMCs of patients with cancer and that the use of the LAMP sequence enhanced CD8-positive and CD4-positive Tcell responses. 38 hTERT-specific T lymphocytes have been generated successfully in patients with metastatic prostate cancer after vaccination with hTERT-DCs. 40 Based on the immunological responsiveness of AML, the high expression of telomerase in AML, and the preclinical and clinical evidence of the induction of effective and specific T-cell responses by telomerase-targeted vaccinations, we conducted a phase 2 clinical trial in which patients with AML in first complete remission (CR1) or second complete remission (CR2) for whom no allogeneic hematopoietic stem cell transplantation option was available received repeated doses of the hTERT-DC vaccine.
MATERIALS AND METHODS
The phase 2 clinical trial was a multicenter, open-label study with the primary objectives of establishing: 1) the feasibility of the manufacture of hTERT-DCs; and 2) the safety and tolerability of the vaccine in patients with AML in CR at the time of screening. Secondary objectives were to evaluate immunological responses to hTERT-DCs in patients with AML and to determine the time to disease recurrence. The study enrolled 33 patients between October 2007 and December 2009. This report provides safety data through termination of the study in December 2010. Long-term follow-up of the patients for disease recurrence as of the time of last follow-up at their latest office visit was performed from November 2013 through February 2014. The clinical trial was conducted after clearance by the US Food and Drug Administration and the Institutional Review Boards at each clinical trial site. Investigators obtained informed consent from each patient. The trial is registered on ClinicalTrials.gov (ClinicalTrial.gov identifier NCT00510133).
Patients
Patients aged 18 years were eligible if they had a diagnosis of AML in CR1 with intermediate-risk or high-risk cytogenetics or in CR2 with a CR1 duration of >6 months. Patients with AML in CR1 were eligible after induction chemotherapy and may or may not have received consolidation therapy provided they had completed and recovered from induction chemotherapy within 6 months of screening. Patients may have completed up to 4 cycles of consolidation chemotherapy or may have undergone up to 3 additional cycles of consolidation chemotherapy, including autologous stem cell transplantation. Patients were required to be in CR within 4 weeks before screening. Eastern Cooperative Oncology Group performance status had to be <1, and with adequate hepatic and renal function. Patients were excluded if they had any of the following: good-risk cytogenetics as defined by the presence of t(15;17), t(8;-21), inv(16), or t(16:16) as the sole cytogenetic abnormality; central nervous system or leptomeningeal disease; planned or expected allogeneic stem cell transplantation within 6 months of screening; documented allergy to penicillin or beta-lactam antibiotics; active or ongoing autoimmune disorder; active second malignancy or history of another malignancy within the last 2 years; clinically significant pulmonary or cardiovascular disease; known immunodeficiency disorder; or active or serious acute or chronic infection. Figure 1 provides a study schema diagram. After providing informed consent, eligible patients proceeded with a large-volume leukapheresis (20-24 L) for up to 6 hours, using a commercially available apheresis system (COBE Spectra; CaridianBCT, Lakewood, Colo). The goal of the Original Article leukapheresis was to provide sufficient PBMC to produce at least 12 doses of hTERT-DCs for patient administration plus additional doses for quality testing and archiving of retention samples. Cells were collected and shipped via overnight delivery to a central facility (Lonza Inc, Walkersville, Md). Autologous hTERT-DCs were produced as reported for a previous prostate cancer clinical trial. 40 Immature DCs were electroporated with an mRNA construct encoding hTERT amino acids 168 through 1132 and the lysosomal targeting sequence (LAMP-1). 40 Further culture induced a mature DC phenotype. 40 The mean time for the production and release of hTERT-DCs was 8.5 weeks.
Study Design
hTERT-DCs were supplied as a sterile, cryopreserved cell suspension. For each injection, a single vial of hTERT-DC product was thawed, washed, and concentrated for dosing. Two samples of prepared cells were sent separately for gram stain and 14-day sterility testing. The hTERT-DCs then were introduced into a labeled delivery syringe. Patients were vaccinated with hTERT-DCs by intradermal injection at the time of confirmation of a negative gram stain test. hTERT-DCs were administered as 6 weekly primary vaccinations. Six biweekly boost vaccinations then were initiated after 4 weeks of rest. Vaccination injection sites were rotated between the upper arms and upper thighs. In cases in which >12 doses were available, patients were offered an extended postboost vaccination administered on a 28-day schedule until the supply was exhausted, the patient or physician chose to discontinue dosing, or the patient was removed from the study because of disease progression or another reason.
Safety Assessments
Patients were evaluated weekly during the primary vaccination period and then monthly during the boost vaccination period through week 54. Thereafter, patient follow-up was conducted approximately every 3 months until disease recurrence/progression of leukemia; death; any other withdrawal from the study; or termination of the study by the original sponsor for reasons not related to safety in December 2010, which was approximately 1 year after the last patient initiated treatment.
The clinical trial was terminated in December 2010 for non-safety-related reasons by the original sponsor (Geron Corporation), approximately 1 year after the last patient underwent leukapheresis. In late 2013, the new sponsor (Asterias Biotherapeutics) performed a long-term follow-up analysis of disease recurrence among those patients who had received hTERT-DCs.
Disease Recurrence Assessments
Disease recurrence was assessed from the time of the first hTERT-DC vaccination. CR was defined by the presence of <5% blasts in bone marrow aspirates, an absolute neutrophil count >1000/lL, a platelet count 100,000/lL, transfusion independence, and the absence of Auer rods. Early disease recurrence was defined by the presence of <20% bone marrow blasts, <5% blood blasts, an absolute neutrophil count >400/ lL, and a platelet count >30,000/lL in the absence of bleeding and infection. For patients in CR at the initiation of the vaccination schedule, recurrence-free survival was defined as the time to morphologic disease recurrence or other evidence of disease progression. Disease recurrence was monitored throughout the study until study termination in December 2010, which was approximately 1 year after the last patient was enrolled. Additional long-term follow-up for disease recurrence was performed again in late 2013 or early 2014. (20-24 L) . Cells were collected and shipped to a central facility, at which human telomerase reverse transcriptase (hTERT)-expressing autologous dendritic cells (hTERT-DCs) were produced. The mean time for the production and release of hTERT-DCs was 8.5 weeks. hTERT-DCs were supplied as a sterile, cryopreserved cell suspension stored in the vapor phase of liquid nitrogen until the day of vaccination. Patients were vaccinated with hTERT-DCs by intradermal injection. hTERT-DCs were administered as 6 weekly primary vaccinations. Six biweekly boost vaccinations then were initiated after 4 weeks of rest. When >12 doses were available, patients were offered extended postboost vaccination administered on a 28-day schedule until the supply was exhausted, the patient or physician chose to discontinue dosing, or the patient was removed from the study for disease progression or other reasons. AML indicates acute myeloid leukemia; BM, bone marrow; CMO, Contract Manufacturing Organization; CR, complete remission. hTERT-specific T-cell responses in PBMCs were assessed by enzyme-linked immunospot assay (ELISPOT) analysis. For this analysis, PBMCs were collected: 1) before vaccination with hTERT-DCs; 2) after the third and sixth primary hTERT-DC vaccinations; 3) after the 4-week rest period; and 4) after hTERT-DC boosts 1, 3, 5, and 6. Patient PBMC samples were stimulated with 1 lg/mL of 1 of 3 hTERT peptide pools (Biosyn, Lewisville, Tex.) and cultured in AIM V media (Life Technologies, Gaithersburg, Md) containing 5% human AB serum (Valley Biomedical, Winchester, Va) for 7 days at 378C at 5% carbon dioxide. The 3 hTERT peptide pools consisted of 281 overlapping peptides (approximately 94 peptides per pool) that spanned the entire hTERT protein. hTERT peptide pool 1 spanned hTERT amino acids 1 to 387, pool 2 spanned hTERT amino acids 377 to 763, and pool 3 spanned hTERT amino acids 753 to 1132. Further details are provided in the Supporting Information section. The frequency of T cells specific for each hTERT peptide pool was determined by subtracting the mock control spots from the number of spots observed in response to the hTERT peptide pools. A patient was considered to be positive for an hTERT T-cell immune response if a change in the number of interferon c (IFN-c) spots of 2.5-fold as assessed by ELI-SPOT assay for at least 1 of the 3 hTERT peptide pools was observed after vaccination compared with prevaccination levels. A minimum of 35 spots per 1310 6 cells was required.
Analysis of hTERT Peptides Targeted by PB-Derived, hTERT-Specific T Cells After Administration of hTERT-DCs
Details regarding the methods used for this analysis can be found in the Supporting Information.
Delayed-Type Hypersensitivity Measurement
After administration of hTERT-DCs, delayed-type hypersensitivity (DTH) was self-reported by patients who received at least 3 doses of hTERT-DCs. Patients selfmeasured and recorded the presence or absence of induration and the size of the induration at the vaccination site in a daily patient diary. A patient was considered to be a DTH responder if an induration measuring 5 mm (0.2 inches) in diameter was observed at the injection site 24 to 72 hours after administration of the third or subsequent vaccinations.
Wilms Tumor 1 Assessment by Reverse Transcriptase-Polymerase Chain Reaction
Quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) for Wilms tumor 1 (WT-1) was conducted (Genzyme Analytical Services, Cambridge, Mass) on RNA samples derived from patient PB collections at baseline and after immunization with the hTERT-DCs.
RESULTS

Patient Disposition and Characteristics
A total of 33 patients were enrolled in the clinical trial and underwent leukapheresis (Table 1 ). Of these, 21 patients received hTERT-DCs. The most frequent primary reason for study discontinuation was disease progression (9 patients) and other reasons (13 patients), which included failure to produce the hTERT-DC vaccine (9 patients) (see below). Table 2 provides the demographic and other baseline characteristics of the study population. The median age of the patients was 58 years (range, 30-75 years), and the median duration from the time of the diagnosis of AML to leukapheresis was approximately 7 months.
Feasibility of hTERT-DC Production
All 33 patients who were enrolled in the study proceeded to undergo leukapheresis. A median/mean of 1.1310 10 (standard deviation, 8.8310 9 ) of viable white blood cells was collected per patient. hTERT-DCs were prepared successfully for 24 patients. hTERT-DCs were not released for 9 patients due to the collection of insufficient cells in the leukapheresis product (1 patient), poor maturation or assessment of maturation of the DCs (6 patients), or a lack of telomerase expression (2 patients). Two of these 24 patients (8%) required 2 leukapheresis products to produce sufficient hTERT-DCs for all intended primary and boost vaccinations. Three of the 23 patients (13%) developed florid disease recurrence during the period of hTERT-DC preparation and were not eligible for vaccinations. Therefore, a total of 21 patients (64%) were eligible to receive the hTERT-DC vaccination, 19 of whom were in CR (16 in CR1 and 3 in CR2) and 2 of whom had early disease recurrence. Two patients in early disease recurrence who had developed disease progression after leukapheresis were permitted as per protocol to proceed with vaccination.
Dosing of hTERT-DCs
All 21 patients received 3 doses of hTERT-DCs. The median number of hTERT-DC vaccinations received by patients was 19 (range, 3-32 vaccinations). Twenty of the 21 patients (95%) received the full complement of 6 primary vaccinations and 13 patients (62%) received all 6 intended primary and boost vaccinations (see Supporting Information Table 1 ).
Adverse Events
Adverse events (AEs) were monitored and reported for the leukapheresis and the hTERT-DC treatment periods. Supporting Information Table 2 provides the frequency of AEs and serious adverse events (SAEs) in patients receiving at least 1 hTERT-DC dose. During the leukapheresis period, 15% patients (5 of 33 of patients) developed AEs. Three patients reported paresthesia, 1 had nausea, and 1 patient experienced chills. All AEs related to leukapheresis were mild (grade 1) and resolved within 1 day of onset, and none was considered serious. All AEs were graded using National Cancer Institute Common Terminology Criteria for Adverse Events.
Of the 21 patients who received hTERT-DCs, 20 patients (95%) reported at least 1 AE after hTERT-DC treatment was initiated (treatment emergent), with 6 patients (29%) having at least 1 AE with a severity grade 3 (see Supporting Information Table 2 ). The treatmentemergent AEs may or may not have been related to the hTERT-DCs. Supporting Information Table 3 summarizes the distribution of treatment-emergent AEs reported in patients who received at least 1 dose of hTERT-DCs. Table 3 summarizes the hTERT-DC-related AEs in patients who received hTERT-DCs. In this study, hTERT-DC-related AEs were defined as those events Abbreviations: AML, acute myelogenous leukemia; ANC, absolute neutrophil count; SD, standard deviation. a Duration was calculated from the time of diagnosis to the date of leukapheresis. In cases in which a second leukapheresis was required to produce the human telomerase reverse transcriptase (hTERT)-expressing autologous dendritic cells, the duration was calculated as the time to the second leukapheresis. For one subject, the duration was calculated from the time of diagnosis of AML to the first leukapheresis procedure because the patient had product released from 2 leukapheresis procedures and was vaccinated with each lot, respectively. having a possible, probable, definite, or unknown relationship to the immunotherapy. hTERT-DC-related AEs were reported in 9 of the 21 patients (43%). These included hTERT-DC vaccine site reactions, which were mild and consisted of grade 1 erythema and induration. During the hTERT-DC treatment period, a total of 6 patients (29%) who received hTERT-DCs experienced AEs of grade 3. Fatigue and headache, which each occurred in 24% of patients (5 of 21 patients), were the most common AEs reported. A summary of the AEs of grade 3 is provided in Table 4 . Of those AEs, 3 were SAEs affecting 2 patients (10%) who received hTERT-DCs. One patient experienced grade 4 idiopathic thrombocytopenic purpura, which resulted in hospitalization and platelet infusion and was considered possibly related to the hTERT-DC vaccine. This patient eventually developed disease recurrence with AML. The other patient with 2 SAEs experienced grade 3 perforated appendicitis and small intestinal obstruction that resolved with surgery; the latter SAEs were considered to be unrelated to the hTERT-DC vaccine whereas the former was considered to be possibly related. There were no safety-related patient deaths reported during the study period.
Assessment of Autoimmunity
To assess the potential induction of autoimmunity after hTERT-DC vaccination, PB samples were assessed for antinuclear antibodies at baseline, after the fourth and sixth vaccinations, and at multiple time points during the boosting phase among 20 patients who received hTERTDCs. Thirteen of 20 patients (65%) had no detectable antinuclear antibodies before and after all vaccinations with hTERT-DCs. Three of the 20 patients (15%) had detectable antinuclear antibodies before and during the vaccination period. For the remaining 4 patients (20%), antinuclear antibodies were not detectable before vaccination and were detected as transiently weakly positive in 1 of 21, 1 of 23, 2 of 15, and 1 of 7 postvaccination determinations.
DTH Responses
Patient reactions to hTERT-DCs generally were local reactions. Patient diaries indicated that some patients experienced no changes at the injection site after the administration of hTERT-DCs, whereas other patients reported redness and swelling that generally resolved within 3 days. Patients reported hTERT-DC injection site pain as none to mild, and injection site itching and whole body itching as none to moderate. No patients reported any severe ratings for DTH local or systemic reactions. 
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Positive DTH reactions were observed from primary vaccination doses 3 or 6 in 8 of the patients. The additional 3 DTH responses were observed either in the boost (1 patient) or extended-boost (2 patients) phase.
hTERT Immune Responses
The presence of T-cell immune responses to hTERT was monitored using IFN-c ELISPOT analysis of PBMCs collected serially before and after the administration of hTERT-DCs. This analysis entailed ELISPOT assays against 3 pools of overlapping hTERT peptides that spanned the amino acids 168 to 1132 of hTERT. This analysis was completed for the 19 patients who were administered hTERT-DCs in either CR1 or CR2. Two patients who received hTERT-DCs in early disease recurrence developed rapid disease progression and were taken off treatment in the primary vaccination stage. Table 5 provides a summary of the ELISPOT data and lists the patients who had detectable hTERT T-cell responses at given time points after vaccination. Detectable immune responses were observed across subjects of all ages, including those aged >60 years. Supporting Information Figure 1 provides actual examples of ELISPOT data from representative patients who were positive and negative for hTERT-specific T-cell responses.
Eleven of the 19 patients (58%) receiving hTERT-DC vaccinations while in CR developed positive hTERT T-cell responses at 1 time points after the administration of the hTERT-DCs. The kinetics regarding the development of detectable PB hTERT-specific T cells varied among patients, some of whom had evidence of T-cell responses after the third vaccination with hTERT-DCs. Others did not develop measurable hTERT T-cell responses until the boost period. Eight of 11 patients (73%) with hTERT-specific T cells had measurable T-cell responses at 2 additional time points after hTERT-DC vaccination.
Further studies were conducted to identify hTERT peptide epitopes recognized by the hTERT-specific T cells found after the administration of hTERT-DCs. For this analysis, 2 patients who were identified as homozygous (patient 13 in Table 5 ) or heterozygous (patient 16 in Table 5 ) for the HLA-A*03:01 allele were used because the majority of hTERT-specific T cells found in these patients targeted pool 2 peptides spanning hTERT amino acids 377 through 763. Similarly, another 3 patients (patients 2, 5, and 17 in Table 5 ), all of whom were homozygous for HLA-A*02:01, were selected. Computational analyses were used to predict "hi," "low," or "non" affinity hTERT peptides for HLA-A*03:01 or HLA-A*02:01 (see Supporting Information Fig. 2 ). For the 2 HLA-A*03:01 patients and the 3 HLA-A*02:01 patients, PBMCs were assessed for their stimulation by "hi," "low," and "non" hTERT peptides (Fig. 2) . In the context of either HLA-A*03:01 or HLA-A*02:01, significantly greater hTERT-specific T-cell responses were observed for the "low" pool and "non" pool peptides compared with "hi" pool peptides (Fig. 2) The results suggest that the hTERT-specific T-cell responses that were observed at the time of hTERT-DC administration primarily targeted peptides with a low affinity for HLA. Further analysis was performed on PBMCs from the 2 patients carrying the HLA-A*03:01 allele and the 3 patients carrying the HLA-A*02:01 allele to deconvolute the hTERT peptides with "low" affinity to which the hTERT-specific T cells were responding (see Supporting Information Figs. 3 and 4) . The results suggest the hTERT-specific T cells from the these patients were stimulated by a similar array of "low" affinity peptides; however, there was some difference with regard to the frequency of hTERT-specific T cells for any given "low" affinity peptide between the subjects. The identities of the "low" affinity binding peptides are provided in Supporting Information Table 4 .
Disease Recurrence
A total of 19 patients who were in CR at the time of the initiation of the vaccination period were followed for disease recurrence. Table 6 provides a summary of disease recurrence among the 19 patients in CR who received hTERT-DCs. Supporting Information Table 5 provides a listing of the disease recurrence status of each individual patient. At the time the study was terminated in December 2010, 14 of 19 patients (74%) (median follow-up,18 months) who received hTERT-DCs during CR remained free of disease recurrence (data not shown). Of the 14 patients who remained free of disease recurrence, 9 (64%) developed hTERT-specific T-cell responses during the vaccination period. Two of the 5 patients who developed disease recurrence (40%) had developed detectable hTERT-specific T-cell responses. Of the 3 patients who were in CR2 at the time of vaccination, all 3 remained in CR (median follow-up, 24 months). Two of the 3 patients in CR2 developed immune responses to hTERT. The study also included 7 patients aged >60 years, a group typically considered to be at high risk of disease recurrence. As of the time of the study termination in December 2010, 5 of these 7 patients (71%) remained free of disease recurrence (median follow-up, 18 months), with all 5 patients developing T-cell immune responses to hTERT. WT-1 biomarker levels 41, 42 also were assessed by quantitative RT-PCR in PB samples collected periodically during the hTERT-DC vaccination period. Only those patients who had developed disease recurrence during the vaccination period were found to demonstrate detectable WT-1 levels (see Supporting Information Table 6 ).
After long-term follow-up, 11 of 19 patients who received hTERT-DCs in CR were free of disease recurrence (median follow-up, 52 months) at the time of last follow-up (Table 6 ). Of the 3 patients who received hTERT-DCs in CR2, 2 were still free of disease recurrence at 50 months and 59 months, respectively, after the initiation of vaccination, whereas the third patient was lost to follow-up at 2 years. Both of the recurrence-free patients in CR2 developed specific T-cell immune responses to telomerase. In addition, 4 of the 7 patients (57%) aged 60 years at the time of the administration of hTERT-DCs remained free of disease recurrence (median follow-up, 54 months). All 4 of these patients had developed hTERT-specific T-cell responses during the vaccination period. Figure 3 shows a Kaplan-Meier curve of the recurrence-free survival of all patients in CR and those who were aged 60 years at the time of first vaccination.
DISCUSSION
The current clinical trial was designed to establish the feasibility of the production of hTERT-DCs from patients with AML in CR and to determine the safety and activity of this DC immunotherapy. hTERT-DCs successfully were produced from 73% of patients enrolled in the trial, were cryopreserved, and yielded an average of 35 doses (standard deviation, 14.8 doses) of 1310 7 hTERT-DCs per production run.
The leukapheresis and hTERT-DC vaccine were found to be well tolerated in the current study, in which up to 32 serial doses were administered (median, 17 doses). Treatment-related AEs generally were those associated with AML such thrombocytopenia and neutropenia; skin/tissue disorders such as erythema, rash, and vitiligo; and administration site conditions such as injection site bruising, induration, and pruritus. Only one patient experienced a grade 4 SAE, which was deemed possibly related to the hTERT-DC vaccine. This SAE, idiopathic thrombocytopenic purpura, led to hospitalization and platelet transfusion. As another assay of the potential induction of autoimmune disease in patients treated for AML, antinuclear antibody assessments were made before and after vaccination with hTERT-DCs. hTERT-DCs were not found to induce sustained antinuclear immune responses, even in patients who received >20 doses. hTERT-specific T-cell responses were induced in 58% of patients. In these individuals, hTERT-specific T cells first were detected at varying time points throughout the primary vaccination, rest, and boost periods. It is not clear whether such hTERT-specific T-cell immune responses were absent in the remaining 42% of patients or whether the frequency of the hTERT-specific T cells was below the level of detection of approximately 1 in 10 5 PB T cells.
The hTERT epitopes modulating hTERT-specific T cells after administration of the hTERT-DCs were analyzed for 2 patients who were positive for the class I major histocompatibility antigen HLA-A*03:01. The analysis demonstrated that the majority of targeted peptides demonstrating positive hTERT-specific T-cell responses were predicted to have low affinity for HLA-A*03:01. Similar results were found in the analysis of hTERT-specific T cells from patients in the trial carrying the HLA-A*02:01 allele. This finding may be related to the fact that hTERT is a self-antigen and T cells specific to high-affinity epitopes may be deleted during development by negative selection. 43 With a median follow-up of 52 months, approximately 58% of patients in the current study who were immunized with hTERT-DCs were free of disease recurrence as of their last follow-up visit. Moreover, 4 of 7 patients aged 60 years (57%) remained free of disease recurrence with a median follow-up of 54 months. There was no correlation noted between recurrence-free survival and the CR duration before vaccination. Moreover, there was no correlation noted between recurrence-free survival and the existence of detectable hTERT-specific T-cell responses.
Several advancements in both the manufacture and use of hTERT-DCs currently are being evaluated to improve the successful production of hTERT-DCs along with their activity in patients. For example, refinements in the hTERT-DC production process, including more automated production procedures and the use of shorter, yet sensitive, assays to detect Mycoplasma, could lead to higher success rates and faster delivery to patients. These changes are anticipated to reduce the time from leukapheresis to vaccination from an average of 8.5 weeks in the current study to 3 to 4 weeks in the future. To increase the potency of the DCs, modifications to the DCs themselves to upregulate immunostimulatory activity could be considered to enhance the generation of cytotoxic hTERTspecific T-cell responses. [44] [45] [46] Further development of more sensitive monitoring assays to assess immunostimulatory activity of the hTERT-DCs and immunological activity at the tumor site could be critically important for determining activity in patients. Finally, with regard to the clinical use of hTERT-DCs, the current study was initiated in 2007, and extensive cytogenetics analyses were not included as part of the trial. The incorporation of cytogenetic profiling of patients in future clinical studies could provide better insights into those patients who might benefit the most from hTERT-DC immunotherapy.
Although only a small number of patients were included in the current study, the recurrence-free survival across all groups was favorable compared with historical controls. In a report assessing the risk of disease recurrence in patients with AML stratified by risk, the cumulative incidence of disease recurrence was reported to be approximately 60% and 90%, respectively, at 3 years in patients with AML with intermediate-risk and high-risk cytogenetics. 47 Overall survival at 3 years was approximately 30% and 10%, respectively, for the same patient subgroups. 47 Among patients with AML who are aged >60 years, only 10% to 20% of patients are reported to survive 3 years from the time of diagnosis. 48, 49 The recurrencefree survival observed in the current study exceeds that reported historically, but further clinical confirmation of these results is necessary. The potential improvement in recurrence-free survival is supported by preclinical models in which telomerase activity is robust in leukemic stem cells and the inhibition of telomerase impairs leukemia progression and delays disease recurrence after chemotherapy. 50 If these results are repeated in additional clinical trials, hTERT-DCs could provide a safe form of immunotherapy with which to prolong recurrence-free survival in patients with AML in CR. The approach would complement new therapeutic regimens currently in development that seek to increase the frequency of induction of CRs.
FUNDING SUPPORT
Geron Corporation was responsible for initiating, conducting, and funding this clinical trial.
CONFLICT OF INTEREST DISCLOSURES
Laurence Elias, Jane S. Lebkowski, Anita Reddy, Kevin P. Nishimoto, and Edward Wirth were employees of Geron Corporation during the execution of the trial. Asterias Biotherapeutics purchased the human telomerase reverse transcriptase (hTERT)-expressing autologous dendritic cells (hTERT-DCs) technology from Geron and Jane S. Lebkowski, Edward Wirth, Kevin P. Nishimoto, Debasish Sen, and Casey Case are employed by Asterias. Hanna J. Khoury and John F. DiPersio have served on a clinical advisory panel meeting for Asterias Biotherapeutics.
